{"id":"ifupinostat-hydrochloride-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting histone deacetylases, ifupinostat increases acetylation of histone and non-histone proteins, leading to altered chromatin structure and reactivation of tumor suppressor genes. This mechanism also enhances immune cell function and can sensitize cancer cells to other therapies, making it a potential combination agent in oncology.","oneSentence":"Ifupinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes to promote anti-tumor gene expression and immune activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:34.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (phase 3 development)"},{"name":"Solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BEBT-908 for Injection","CUDC-908"],"phase":"phase_3","status":"active","brandName":"Ifupinostat Hydrochloride for Injection","genericName":"Ifupinostat Hydrochloride for Injection","companyName":"BeBetter Med Inc","companyId":"bebetter-med-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ifupinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes to promote anti-tumor gene expression and immune activation. Used for Hematologic malignancies (phase 3 development), Solid tumors (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}